Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection

Transpl Infect Dis. 2007 Sep;9(3):256-9. doi: 10.1111/j.1399-3062.2007.00261.x. Epub 2007 Jul 1.

Abstract

We present a case of serious treatment-refractory acyclovir- and foscarnet-resistant herpes simplex virus (HSV) type-1 orolingual infection that responded to oral cidofovir rinses after failure of acyclovir and foscarnet therapy. The use of 3% cidofovir in a saline rinse for refractory mucosal HSV infection appears promising but needs prospective evaluation.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Topical
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects
  • Cidofovir
  • Cytosine / administration & dosage
  • Cytosine / adverse effects
  • Cytosine / analogs & derivatives*
  • Drug Resistance, Multiple, Viral
  • Female
  • Herpesvirus 1, Human / isolation & purification*
  • Humans
  • Immunocompromised Host
  • Middle Aged
  • Mouthwashes
  • Organophosphonates / administration & dosage*
  • Organophosphonates / adverse effects
  • Stem Cell Transplantation
  • Stomatitis, Herpetic / drug therapy*
  • Stomatitis, Herpetic / immunology*
  • Stomatitis, Herpetic / virology

Substances

  • Antiviral Agents
  • Mouthwashes
  • Organophosphonates
  • Cytosine
  • Cidofovir